At what enterprise value was IMANEO acquired in 2023?

During the acquisition of IMANEO by PARQUEST CAPITAL in 2023, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of IMANEO when it was acquired by PARQUEST CAPITAL?

The estimated EV/EBITDA multiple for IMANEO is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was IMANEO acquired by PARQUEST CAPITAL?

IMANEO was acquired by PARQUEST CAPITAL in 2023.

What was the revenue of IMANEO at the time of the deal?

The revenue of IMANEO at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of IMANEO during the acquisition?

IMANEO's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the IMANEO acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the IMANEO deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://parquest.fr/fr/presse/cp-imaneo-06-23/

← DATABASE

Home Database Healthcare & PharmaIMANEO

06/2023

IMANEO acquired by PARQUEST CAPITAL

FRANCE Health Providers / Outpatient Care / Radiology EV 100M - 350M EUR

Context

Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector. This strategic operation facilitates the merger of three independent radiology practices into a single unified platform. The associate radiologists, who were already shareholders in their respective legacy firms, reinvested significantly to retain nearly 50% of the new group's capital. The investment strategy is focused on structuring the newly created entity's management and operations to allow medical staff to focus on clinical practice while providing the financial resources for aggressive organic and external growth. A unitranche debt facility, including dedicated capital expenditure lines, was secured to fund innovation in medical technology and the acquisition of additional radiology practices across the region.

IMANEO, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Established in 2023 through the strategic merger of three prominent medical imaging entities based in Montpellier (CRP, Imacam, and I-Seris), Imaneo is a major regional player in the Occitanie healthcare market. The group provides comprehensive diagnostic imaging services through a collaborative network of specialized clinics. With a team of 70 associate radiologists and approximately 350 employees, the organization focuses on delivering high-quality medical care while leveraging shared resources to invest in technological advancements. The group is structured as a unified platform designed to integrate modern tools, including artificial intelligence solutions for diagnostics, and to attract new medical talent. By consolidating local expertise, the entity serves as a medical-led platform capable of addressing the growing demand for specialized outpatient care in southern France.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
08/2023	BAIN CAPITAL	ESTIA HEALTH	AUSTRALIA	Health Providers	Following a five-month bidding process, Bain Capital has entered into a definitive Scheme Implementation Agreement to acquire 100% of the share capital of Australian aged care operator Estia Health Limited
07/2023	MEDIAN KLINIKEN	HESTIA ALLIANCE	SPAIN	Health Providers	MEDIAN Group, backed by Waterland Private Equity, acquired Hestia Alliance, one of Spain's largest private post-acute and mental health care providers, marking MEDIAN's first entry into the Spanish healthcare market
06/2023	ARDIAN	MON VETO	FRANCE	Health Providers	Ardian acquired a minority stake (approximately 20%) in Mon Veto through a primary capital increase. This "pure cash-in" operation was designed to strengthen the group's equity base without any cash-out for the founding veterinarians
11/2022	RADNET	HEART & LUNG IMAGING	UNITED KINGDOM	Health Providers	RadNet, a US-based medical imaging specialist, has acquired a 75% majority stake in Heart & Lung Imaging Limited (HLH), a UK-based teleradiology network focused on detecting and diagnosing lung and cardiovascular diseases
10/2022	CBPE CAPITAL	VEINCENTRE	UNITED KINGDOM	Health Providers	CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics
09/2022	ORADIANSE	REVEL	FRANCE	Health Providers	Oradianse, a leading group of radiologists, has acquired a radiology practice in Revel, located in the Haute-Garonne region near Toulouse. This move is part of the company's territorial development strategy, aimed at strengthening its presence in the Occitanie region and consolidating its national network of medical imaging centers
09/2022	EURAZEO	IMAPOLE	FRANCE	Health Providers	Eurazeo has partnered with Bpifrance to complete a major investment of over EUR 50 million in Imapole. This investment marks a strategic turning point in the professionalization of regional medical imaging groups in France
08/2022	FREEMAN SPOGLI	EVERVET PARTNERS	UNITED STATES	Health Providers	Freeman Spogli & Co. made a significant investment in EverVet Partners, partnering alongside existing investor Tailwind Capital while EverVet's founders and management retained meaningful equity stakes
07/2022	LATOUR CAPITAL	PHARMACIE LAFAYETTE - GROUPE HYGIE31	FRANCE	Health Providers	Latour Capital and Bpifrance acquired a majority stake in Hygie31, the holding company of Pharmacie Lafayette, from Five Arrows (Rothschild & Co). The deal aims to accelerate the group's development in France and Europe through organic growth and an ambitious buy-and-build strategy
07/2022	INFRAVIA CAPITAL	UNIVET	FRANCE	Health Providers	InfraVia Capital Partners acquired a minority stake in Univet from Platina Equity Solutions, which had been a partner since 2018. The transaction was structured as a combination of secondary share purchases and a primary capital increase, financed entirely through equity from InfraVia's EUR5 billion European Fund V

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IMANEO by PARQUEST CAPITAL are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: imaneo

Acquirer: parquest capital